Simple Summary Chimeric antigen receptor–engineered T cells are an innovative therapy in
hematologic malignancies, especially in patients with refractory/relapsed B-cell lymphomas …

Chimeric antigen receptor (CAR) T-cell therapy is a cellular therapy in which the patient's T
cells are enhanced to recognize and bind to specific tumor antigens. CAR T-cell therapy was …

Purpose Chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients
with relapsed or refractory (r/r) aggressive B-cell lymphomas. The prognosis of patients who …

Purpose Chimeric antigen receptor (CAR) T-cell therapy has been confirmed to benefit
patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). It is …

Abstract Background and Purpose Chimeric antigen receptor (CAR) T‐cell therapy is
potentially associated with treatment‐related toxicities mainly consisting of cytokine release …

Majority of non-Hodgkin lymphoma (NHL) patients who achieve partial response (PR) or
stable disease (SD) to CAR T-cell therapy (CAR T) on day+ 30 progress and only 30 …

Background In our current work, an 18F-FDG PET/CT radiomics-based model was
developed to assess the progression-free survival (PFS) and overall survival (OS) of patients …

Simple Summary Cancer immunotherapy is a type of cancer treatment that uses the immune
system to fight cancer cells. Some of these treatments stimulate the immune system, while …

Adoptive T‐cell therapy (ACT), which is an important type of live cell therapy, has achieved
unprecedented success in treating hematological malignancies. Recent studies have shown …

CAR T-cells is an innovative treatment for relapsed/refractory aggressive B cell lymphomas,
initially proposed as third-line therapy and beyond, now allowed as soon as second-line …